Selective degradation of TBK1 uncovers mechanistic insights into blocking ccRCC progression
- 7 April 2026
- journal article
- Published by Elsevier in Cell Chemical Biology
- Vol. 33 (4) , 461-473.e7
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R01CA284591)
- Cancer Prevention and Research Institute of Texas (RR190058)
- University of North Carolina
- American Urological Association
This publication has 43 references indexed in Scilit:
- TANK-binding kinase 1 (TBK1): An emerging therapeutic target for drug discoveryDrug Discovery Today, 2021
- PROteolysis TArgeting Chimeras (PROTACs) — Past, present and futureDrug Discovery Today: Technologies, 2019
- Discovery of GSK8612, a Highly Selective and Potent TBK1 InhibitorACS Medicinal Chemistry Letters, 2019
- Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AMLCell Chemical Biology, 2019
- Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1Journal of Medicinal Chemistry, 2017
- On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer modelsNature, 2016
- Synthesis and structure–activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKε kinasesBioorganic & Medicinal Chemistry Letters, 2012
- Age and Gender Related Differences in Renal Cell Carcinoma in a European CohortJournal of Urology, 2012
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal CarcinomaCancer Cell, 2008